Diarrhoea Predominant Irritable Bowel Syndrome Completed Phase 2 Trials for Ondansetron (DB00904)

Also known as: Diarrhea-predominant Irritable Bowel Syndrome / IBS, Diarrhea Predominant / Irritable Bowel Syndrome With Diarrhea / Diarrhea Predominant Irritable Bowel Syndrome / Diarrhea- Predominant Irritable Bowel Syndrome / Diarrhea Dominant Irritable Bowel Syndrome / Irritable bowel syndrome with diarrhea (disorder) / Irritable bowel syndrome without diarrhea / Irritable colon / Colitis mucous / Mucous colitis / Colon spastic / Spastic colon / Irritable colon syndrome / Functional bowel syndrome / Irritable bowel / Irritable bowel syndrome / Irritable colon (disorder)

IndicationStatusPhase
DBCOND0075933 (Diarrhoea Predominant Irritable Bowel Syndrome)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02757105Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)Treatment